Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
Summary of the evidence on antimicrobial prescribing: delafloxacin
Summary of the evidence on antimicrobial prescribing: cefiderocol
Summary of the evidence on antimicrobial prescribing: imipenem with cilastatin and relebactam
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis
This evidence summary has been updated and replaced by the COVID-19 rapid guideline on vitamin D (NG187).
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
ES24 . Key messages The content of this evidence review was up to date on 1 April 2020. New evidence may have been published since
ES25 . Key messages The content of this evidence review was up to date on 20 April 2020. New evidence may have been published since
ES26 . Key messages The content of this evidence review was up to date on 13 May 2020. New evidence may have been published since